Search clinical trials for: PNEUMOVAX™23

Total 3891 results

Merck Sharp & Dohme LLC

Completed

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Herpes Zoster | Pneumococcal Infection
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)

Pneumococcal Infection
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Estonia, Canada
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Pneumococcal Infections
GlaxoSmithKline

Completed

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

Prophylaxis Invasive Pneumococcal Diseases and Pneumonia

Belgium
Merck Sharp & Dohme LLC

Completed

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Pneumococcal Disease
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (PNEU-WAY)

Pneumococcal Infections

United States, France, Peru, South Africa, Thailand
GlaxoSmithKline

Completed

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

Streptococcus Pneumoniae Vaccines

Sweden
Merck Sharp & Dohme LLC

Completed

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Pneumococcal Infection
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (PNEU-WAY PED)

Pneumococcal Infections

South Africa, Thailand, Ukraine
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

Influenza

Belgium, France
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PNEU-PATH)

Pneumococcal Infections

United States, Korea, Republic of, Spain, Taiwan
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Pneumococcal Infections

United States, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Mexico, Sweden
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Pneumonia, Pneumococcal

United States, Canada, France, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Pneumococcal Infection

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Pneumococcal Disease

United States, Belgium, Chile, France, South Africa, Thailand
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Pneumococcal Infection

France, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden, Chile, Colombia
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

Pneumococcal Disease

Argentina, Australia, Colombia, Germany, Israel, Korea, Republic of, New Zealand, Spain, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)

Pneumococcal Disease

Japan
Cedars-Sinai Medical Center

Completed

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

Crohn Disease | Ulcerative Colitis | Inflammatory Bowel Disease

United States
University of California, Davis

Recruiting

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Asplenia

United States
Rohit Divekar

Completed

Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

Asthma

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (STRIDE-8)

Pneumococcal Infection

United States, Australia, Canada, Chile, Japan, Korea, Republic of, New Zealand, Poland
Naval Health Research Center
U.S. Army Medical Research and Development Command

Completed

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

Pneumonia | Acute Respiratory Disease

United States
Kaiser Permanente
Centers for Disease Control and Prevention

Completed

Pneumococcal Adult-dose Ranging Immunization Study

Pneumonia

United States
National Institute of Allergy and Infectious Diseases...

Completed

Pneumococcal Reference Standard

Pneumococcal Infections

United States
US Department of Veterans Affairs
Albert Einstein College of Medicine; Montefiore Medical Center

Completed

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

HIV Infections

United States
University of Melbourne
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pneumococcal Vaccination of Fiji Infants

Pneumococcal Infections

Fiji
argenx

Completed

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Healthy Volunteers

Netherlands
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

Pneumococcal Infection

Japan
Merck Sharp & Dohme LLC

Completed

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Pneumonia, Pneumococcal

United States
GPN Vaccines

Recruiting

Extension Safety and Immunogenicity Study of GPNV-001

Pneumococcal Infections

Australia
Mayo Clinic

Completed

A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes

Type 1 Diabetes

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Pneumococcal Disease

United States, Sweden
Seema Bhat

Recruiting

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
VA Office of Research and Development

Terminated

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

Aging | Renal Transplantation

United States
GlaxoSmithKline
Affinivax, Inc.

Completed

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Pneumonia, Bacterial | Healthy Volunteers | Pneumococcal Disease

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Unknown

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Pneumococcal Infections | HIV | Pneumococcal Vaccines

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Pneumococcal Infections

United States
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Pneumococcal Disease

Korea, Republic of, Taiwan, Japan
PATH

Completed

Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

Pneumococcal Disease

Gambia
University of Utah
National Cancer Institute (NCI)

Recruiting

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
GPN Vaccines

Recruiting

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Pneumococcal Infections

Australia
University of Minnesota
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease (PNEUMO)

Pulmonary Disease, Chronic Obstructive

United States
University of Florida

Completed

Effect of Obesity on Immune Response to Pneumovax 23 (ROVE)

Obesity

United States
AZ Sint-Jan AV
Pfizer

Completed

13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients

Chronic Kidney Failure

Belgium
Johann Wolfgang Goethe University Hospital

Completed

Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics (PAPSI)

Asthma
Texas A&M University
Philips Healthcare; US Department of Defense - Defense Threat Reduction Agency

Completed

Persistent Readiness Through Early Prediction Immunization Study (PREP DOD)

Inflammatory Response

United States

3

Subscribe